Patent Attorney – Small Corporation – Cambridge, Mass.

Proteostasis Therapeutics Proteostasis Therapeutics is seeking a Patent Attorney with 5+ years experience in patent prosecution. This individual will work with a variety of cross-functional teams to build and maintain a strong intellectual property portfolio in support of the company’s drug discovery and development efforts. The role will also involve exposure to a broad range of non-patent legal issues arising from our extensive support for a range of academic collaborations and pharmaceutical partnerships. The successful applicant will have a MS or PhD degree in a chemical or biological discipline.

• Manage patent assets, including identifying patentable inventions through interactions with project teams, drafting patent applications and responses to PTO correspondence, and determining inventorship
• Conduct periodic patent and scientific literature searches in all
technology areas of the company
• Identify, perform and/or manage patentability and freedom to operate searches, studies and opinions
• Review potential disclosures prior to submission for publication
• Assist with due diligence reviews for licensing efforts
• Negotiate CDA’s, MTA’s, and sponsored research agreements with academic institutions
• Supervise outside counsel; organize and conduct quarterly patent committee meetings
• Educate staff concerning key intellectual property issues

Please submit resume and cover letter to: EOE.

Additional Info:
Employer Type: Small Corporation
Job Location: Cambridge, Massachusetts

Proteostasis Therapeutics, Inc. is the first company dedicated to the discovery of new therapeutics based upon understanding the body’s natural Proteostasis Network. Advances in our ability to characterize and pharmacologically control the Proteostasis Network create new opportunities for ameliorating diseases in a wide number of therapeutic areas. Regulation of the Proteostasis Network is a new approach to drug discovery that will provide the kind of foundational understanding that we have witnessed with other breakthrough treatment paradigms, such as with kinases and G-protein coupled receptors.